pegcetacoplan intravitreal (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

Geographic Atrophy

Pending FDA approval for geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Next:

Pharmacology

Mechanism of Action

Targeted complement-3 (C3) therapy designed to regulate excessive activation of the complement cascade

Geographic atrophy (GA) is an advanced form of age-related macular degeneration

GA is caused by destruction of retinal cells through irreversible lesion growth that is driven by excessive complement activation

C3 is the only target that can precisely control the complement cascade due to its central location

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.